WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: NDA022334_rels, Secondary efficacy endpoint is_documented_by Time to deterioration of ECOG performance status (ECOG PS), Progression-free survival (PFS) - investigator assessed ends_concurrent_with_start Date of randomization, Secondary efficacy endpoint is_documented_by Objective response rate (ORR), Visceral has_component Liver, Metastatic cancer has_component Multiple site, Change in quality-of-life (QoL) scores over time is_derived_from EORTC QLQC30 questionnaire, Visceral has_component Lung, Overall survival (OS) starts_concurrent_with_start Date of randomization, Secondary efficacy endpoint is_documented_by Overall survival (OS), Clinical benefit rate (CBR) has_value Proportion of patients with a best overall response of CR, PR, or stable disease (SD) with a duration of 24 weeks or longer, Progression-free survival (PFS) - investigator assessed ends_concurrent_with_start Date of disease progression, Objective response rate (ORR) has_component Partial response (PR), Objective response rate (ORR) documents Receiving of at least one dose of study drug, Hormone receptor status has_component Estrogen receptor (ER) status, Breast cancer has_component HER2 status, Secondary efficacy endpoint is_used_for ER-positive, Secondary efficacy endpoint is_documented_by Clinical benefit rate (CBR), Metastatic cancer has_component Visceral, Estrogen receptor (ER) status has_value ER-positive, Secondary efficacy endpoint is_documented_by Change in quality-of-life (QoL) scores over time